CCL3L1 ELISA kit
- Known as:
- CCL3L1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-CCL3L1-Mu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- CCL3L1 ELISA kit
Related genes to: CCL3L1 ELISA kit
- Gene:
- CCL3L1 NIH gene
- Name:
- C-C motif chemokine ligand 3 like 1
- Previous symbol:
- D17S1718, SCYA3L, SCYA3L1
- Synonyms:
- G0S19-2, LD78BETA
- Chromosome:
- 17q12 alternate reference locus
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-04
- Date modifiied:
- 2018-05-03
Related products to: CCL3L1 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: CCL3L1 ELISA kit
- Pseudorabies virus (PRV) remains a major threat to the swine industry, particularly due to the emergence of highly virulent PRV variants that have caused severe outbreaks in Asia in recent years. These emerging strains exhibit enhanced pathogenicity and immune evasion, resulting in insufficient protection by traditional inactivated or attenuated vaccines derived from classical strains such as Bartha. Therefore, novel antiviral vaccine strategies with improved immunogenicity are urgently needed. In this study, an attenuated recombinant PRV (rPRV) was constructed from the emerging HNX strain by removing the TK and gE loci and introducing a CCL3L1 expression cassette (HNX-ΔTK/ΔgE-CCL3L1). The immunogenicity and protective efficacy of this recombinant virus were systematically evaluated. HNX-ΔTK/ΔgE-CCL3L1 significantly promoted the activation of bone marrow-derived dendritic cells (DCs) in vitro and enhanced DC activation in lymph nodes (LNs) in vivo. Vaccination with HNX-ΔTK/ΔgE-CCL3L1 induced robust humoral immune responses, including increased virus-neutralizing and glycoprotein B-specific antibody levels observed from the second week post-immunization onward. Furthermore, rPRV-expressed CCL3L1 enhanced T cell-dependent germinal center (GC) responses, resulting in improved protection against lethal PRV challenge. Our results demonstrate that CCL3L1 acts as an effective molecular adjuvant by potentiating humoral immunity through activation of the conventional DC-T follicular helper cell-GC B cell axis, supporting HNX-ΔTK/ΔgE-CCL3L1 as a potential vaccine for the control of emerging PRV variants. - Source: PubMed
Publication date: 2026/08/24
Yao LunHao SiwenZhang ChengjunJin MengyunHu QiaoLuo QingpingWen GuoyuanWu Hao - Repurposing clinically approved antifibrotic agents presents a potential near-term therapeutic strategy to mitigate the extensive fibrotic scarring that follows severe volumetric muscle loss (VML) injury and inhibits functional recovery. We hypothesized that daily oral administration of pirfenidone, an FDA-approved antifibrotic, would mitigate the overwhelming fibrotic response and facilitate functional recovery in a clinically relevant porcine VML model. Yorkshire-cross pigs (n = 12) underwent VML or sham surgery in the peroneus tertius muscle and were subsequently allocated to pirfenidone treatment or untreated controls. At the 4-week study endpoint, the affected muscles underwent comprehensive histological, biochemical, transcriptional and neuromuscular functional assessments. Transcription profiling demonstrated that pirfenidone downregulated key pro-inflammatory cytokine and chemokine regulators involved in excessive fibrosis, including TNF, CCL3L1 and CCL2. While pirfenidone treatment failed to reduce total collagen deposition, evidenced by picrosirius red quantification and hydroxyproline content, it did result in a less dense collagen fibre architecture, suggestive of altered tissue remodelling. However, pirfenidone treatment impaired functional recovery through reduced contractile output and resulted in stagnant weight gain compared to the untreated cohort. This work demonstrates that systemic pirfenidone administration failed to meaningfully reduce fibrosis and subsequently worsened functional capacity following VML, similar to previous antifibrotic studies. The functional deficits and stagnant weight gains observed here underscore a critical knowledge gap regarding the impact of systemic antifibrotics on contractile recovery, necessitating a rigorous re-evaluation of delivery routes, dosages and administration timelines to ensure that future therapies for fibrotic scarring do not inadvertently hinder the physiological recovery of VML-injured muscle. - Source: PubMed
Publication date: 2026/07/30
Motherwell Jessica MEken OndineHernandez Claudia EDearth Christopher LGoldman Stephen M - Neutrophils are major players in innate immune immunity. However, their landscape and functions in colorectal cancer liver metastasis (CRLM) remain poorly understood. Here, using single-cell RNA sequencing and spatial-enhanced-resolution-omics-sequencing (Stereo-seq), we provide a comprehensive transcriptional landscape of tumor-associated neutrophils (TANs) in CRLM. Our analysis reveals that a terminally differentiated pro-tumor neutrophils subset (TAN1), characterized by a glycolysis signature and a senescent phenotype, is significantly enriched in liver metastasis and associated with poor prognosis. Mechanistically, TAN1 arises from other TAN subsets through the upregulation of BHLHE40, driven by glucose deprivation in the metastatic microenvironment. Functionally, TAN1 promotes angiogenesis via VEGFA and recruits immunosuppressive macrophages through potential CCL3L1-CCR1 signaling, thereby fostering an angiogenic immunosuppressive niche. As a result, neutrophil-specific knockout of Bhlhe40 in mice significantly promotes anti-tumor immunity and suppresses tumor growth. In sum, our data uncover the critical role of BHLHE40+ senescent-like neutrophils in shaping the immunosuppressive microenvironment of CRLM. - Source: PubMed
Publication date: 2026/05/19
Chen ZhihangRen XiaoxueZhang YifanKang YoumeiYang YeXu YihangZhou QianLiao ChangyiZeng QianwenLiu XinLin RenxuanYang YuLuo FengShen ShunliPeng SuiLi XiaoxingLong JiantingXu LixiaKuang Ming - As cannabis use continues to rise among people with HIV (PWH), understanding its impact on immune function in this population is becoming increasingly important. To provide new insights on how cannabis modulates immune function, we analyzed single-nucleus multi-omic profiles of peripheral blood mononuclear cells (PBMCs) from PWH to characterize the changes in gene expression and chromatin accessibility associated with chronic cannabis exposure. We identified numerous differentially expressed genes (DEGs) between cannabis users and non-users in each cell type, approximately half of which were unique to individual cell types. Changes in pro- and anti-inflammatory gene expression associated with cannabis use are dependent on cell lineage and type. We identified hundreds of differential chromatin accessibility regions in each cell type, including -regulatory elements correlated with cell-type-dependent DEGs (e.g. in CD4+ T cells and in classical monocytes). Multiple cannabis-associated transcription factors (e.g., , and ) emerge as regulators of the differentially expressed inflammatory genes. Furthermore, cannabis altered the communication between classical monocytes and lymphocytes. These findings indicate that cannabis-induced immunomodulatory effects are profound, dynamic and complex among cell types and that transcriptional changes are regulated at least in part by epigenetic mechanisms. - Source: PubMed
Publication date: 2026/02/27
Li MingruiAsam KesavaDuan XiaokePage Grier PHu YingMartinez ClaudiaCohen Mardge HArchin Nancie MValizadeh AmirHancock Dana BJohnson EricAouizerat Bradley EXu Ke - Limited data exist on the immunoregulatory mechanisms involv ed in thyroid cancer, particularly in aggressive forms. This study aimed at identifying the expression profiles of immune-related genes and miRNAs in anaplastic (ATC) and poorly differentiated thyroid carcinomas (PDTC) associated with papillary carcinoma (PTC) components. Immune-related genes were investigated using the nCounter® PanCancer Immune Profiling Panel in separate ATC and PTC components of 12 cases, and in PDTC component only of nine additional cases associated with PTC. Global miRNAs profiling was also analyzed separately in ATC and PTC components of 8 out of the 12 cases. Comparative analysis between ATC and matched PTC components revealed largely stable gene expression patterns, with only a few genes deregulated. Of these, five genes (MAP3K1, PRKCD, CYFIP2, BLNK, and EPCAM) were downregulated, while six (RIPK2, ITGB1, CCL3L1, ITGA5, PLAUR, and TICAM2) were upregulated in ATC. Furthermore, 54 miRNAs were significantly upregulated in ATC, as compared to PTC components. One of the most regulated pathways was the MAPK signaling, with six of these deregulated miRNAs targeting the MAP3K1 gene. Comparing ATC and PDTC, over 200 genes were differentially expressed between PDTC and ATC samples, involving all major immune-related pathways, with a consistent downregulation in PDTC. In conclusion, ATC displays high levels of expression of immunoregulatory genes as compared to PDTC. Moreover, a subset of genes and miRNAs is significantly de-regulated along progression from PTC to ATC, suggesting their potential role as biomarkers and involvement in key functional mechanisms. - Source: PubMed
Publication date: 2025/09/18
Orlando GiuliaNapoli FrancescaZambelli VanessaMaletta FrancescaCapella GiuliaDuregon EleonoraVolante MarcoPapotti Mauro